{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T19:29:08Z","timestamp":1758655748220,"version":"3.44.0"},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_pp-2025-0005_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Peritoneal regression grade score (PRGS) has emerged a scoring system designed to measure the extent of residual disease following systemic or intraperitoneal therapies in patients with carcinomatosis. Higher (3\u20134) PRG-Scores match with a mediocre treatment response and prognosis. Conversely, lower grades (1\u20132) response are linked to significantly longer overall and progression-free survival periods. This study explores the utility of PRGS in assessing prognosis and optimizing therapeutic strategies for patients with peritoneal metastasis secondary to gastric malignancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_pp-2025-0005_abs_003\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a prospective cohort study, including patients with gastric cancer and peritoneal metastasis undergoing chemotherapy with intent for subsequent cytoreductive surgery. The primary endpoint of the study is to assess the pathological response of peritoneal involvement to primary chemotherapy according to the PRGS. Secondary objectives are to correlate PRGS with some clinical, pathological and molecular features (MMR, PDL1, CPS, HER2) as well as with other clinical and biochemical markers related to chemotherapy response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_pp-2025-0005_abs_004\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This protocol summarizes the current scientific evidence regarding the effectiveness of the PRGS in assessing peritoneal response to targeted therapies. It further hypothesizes its potential utility in evaluating the effects of systemic therapies for gastric cancer with peritoneal metastases, while also defining inclusion and exclusion criteria and outlining a flowchart for its implementation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_pp-2025-0005_abs_005\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our final endpoint is to expand PRGS applications to curative settings and identify factors such as tumor biology and chemotherapy regimens that may guide patient selection for adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer with peritoneal metastasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/pp-2025-0005","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T06:19:20Z","timestamp":1757830760000},"page":"147-152","source":"Crossref","is-referenced-by-count":0,"title":["Clinical utility of the peritoneal pathologic regression in gastric cancer patients associated to peritoneal metastasis. a study protocol"],"prefix":"10.1515","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3104-3567","authenticated-orcid":false,"given":"Silvia","family":"Guerrero-Mac\u00edas","sequence":"first","affiliation":[{"name":"Peritoneal Malignancies Unit , Cancer Treatment & Research Center (CTIC) , Bogota , Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8262-8752","authenticated-orcid":false,"given":"Mar\u00eda Eugenia","family":"Manrique-Acevedo","sequence":"additional","affiliation":[{"name":"Gastrointestinal & Neuroendocrine Tumors Unit , Cancer Treatment & Research Center (CTIC) , Bogota , Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6323-9612","authenticated-orcid":false,"given":"Carlos E.","family":"Bonilla","sequence":"additional","affiliation":[{"name":"Gastrointestinal & Neuroendocrine Tumors Unit , Cancer Treatment & Research Center (CTIC) , Bogota , Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-6318","authenticated-orcid":false,"given":"Magda","family":"Vargas Diaz","sequence":"additional","affiliation":[{"name":"Pathology Oncology , Cancer Treatment and Research Center (CTIC) , Bogota , Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4236-6310","authenticated-orcid":false,"given":"Xavier","family":"Delgadillo","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Sp\u00e9cialis\u00e9e de Chirurgie , Centre M\u00e9dico Chirurgical Volta , La Chaux-de-Fonds , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"unstructured":"National Comprehensive Cancer Network. NCCN clinical Practice Guidelines in oncology: gastric cancer; 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf [Accessed at.1","key":"2025092318543928012_j_pp-2025-0005_ref_001"},{"doi-asserted-by":"crossref","unstructured":"Bonnot, PE, Piessen, G, Kepenekian, V, Decullier, E, Pocard, M, Meunier, B, et al.. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J\u00a0Clin Oncol 2019;37:2028\u201340. https:\/\/doi.org\/10.1200\/JCO.18.01688.","key":"2025092318543928012_j_pp-2025-0005_ref_002","DOI":"10.1200\/JCO.18.01688"},{"doi-asserted-by":"crossref","unstructured":"Burke, EC, Karpeh, MS, Conlon, KC, Brennan, MF. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg, vol 225; 1997. p.\u00a0262\u20137. https:\/\/doi.org\/10.1097\/00000658-199703000-00004. https:\/\/journals.lww.com\/annalsofsurgery\/Abstract\/1997\/03000\/Laparoscopy_in_the_Management_of__Gastric.4.aspx.","key":"2025092318543928012_j_pp-2025-0005_ref_003","DOI":"10.1097\/00000658-199703000-00004"},{"doi-asserted-by":"crossref","unstructured":"Miki, Y, Tokunaga, M, Tanizawa, Y, Bando, E, Kawamura, T, Terashima, M. Staging laparoscopy for patients with cM0, type 4, and large type 3 gastric cancer. World J Surg 2015;39:2742\u20137. https:\/\/doi.org\/10.1007\/s00268-015-3144-z.","key":"2025092318543928012_j_pp-2025-0005_ref_004","DOI":"10.1007\/s00268-015-3144-z"},{"doi-asserted-by":"crossref","unstructured":"Sugarbaker, P. Laparoscopy in the diagnosis and treatment of peritoneal metastases. Ann Laparosc Endosc Surg 2019;4:42. https:\/\/doi.org\/10.21037\/ales.2019.04.04.","key":"2025092318543928012_j_pp-2025-0005_ref_005","DOI":"10.21037\/ales.2019.04.04"},{"doi-asserted-by":"crossref","unstructured":"Reginelli, A, Giacobbe, G, Del Canto, MT, Alessandrella, M, Balestrucci, G, Urraro, F, et al.. Peritoneal carcinosis: what the radiologist needs to know. Diagnostics 2023;13:1974. https:\/\/doi.org\/10.3390\/diagnostics13111974.","key":"2025092318543928012_j_pp-2025-0005_ref_006","DOI":"10.3390\/diagnostics13111974"},{"doi-asserted-by":"crossref","unstructured":"Solass, W, Meisner, C, Kurtz, F, Nadiradze, G, Reymond, MA, B\u00f6sm\u00fcller, H. Peritoneal regression grading score (PRGS) in peritoneal metastasis: how many biopsies should be examined? Pleura Peritoneum 2022;7:179\u201385. https:\/\/doi.org\/10.1515\/pp-2022-0118.","key":"2025092318543928012_j_pp-2025-0005_ref_007","DOI":"10.1515\/pp-2022-0118"},{"doi-asserted-by":"crossref","unstructured":"Solass, W, Sempoux, C, Detlefsen, S, Carr, NJ, Bibeau, F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum 2016;1:99\u2013107. https:\/\/doi.org\/10.1515\/pp-2016-0011.","key":"2025092318543928012_j_pp-2025-0005_ref_008","DOI":"10.1515\/pp-2016-0011"},{"doi-asserted-by":"crossref","unstructured":"Baake, J, Nadiradze, G, Archid, R, K\u00f6nigsrainer, A, B\u00f6sm\u00fcller, H, Reymond, M, et al.. Peritoneal regression grading score (PRGS): first evidence for independent predictive and prognostic significance. Pleura Peritoneum 2023;8:55\u201363. https:\/\/doi.org\/10.1515\/pp-2023-0014.","key":"2025092318543928012_j_pp-2025-0005_ref_009","DOI":"10.1515\/pp-2023-0014"},{"doi-asserted-by":"crossref","unstructured":"Delgadillo, X, W\u00fcthrich, P, Torrent, JJ. Application of pressurized intraperitoneal aerosolization chemotherapy (PIPAC) in peritoneal carcinomatosis of colorectal origin. Revista Mexicana de Coloproctolog\u00eda Enfermedades del Ano, Recto y Colon 2024;19:67\u201375.","key":"2025092318543928012_j_pp-2025-0005_ref_010","DOI":"10.35366\/115700"},{"doi-asserted-by":"crossref","unstructured":"Groh, EM, Gupta, S, Brown, ZJ, Enewold, L, Gamble, LA, Hernandez, JM, et al.. Staging laparoscopy is underutilized in the management of gastric adenocarcinoma. Ann Surg Oncol 2020;27:1473\u20139. https:\/\/doi.org\/10.1245\/s10434-019-08077-1.","key":"2025092318543928012_j_pp-2025-0005_ref_011","DOI":"10.1245\/s10434-019-08077-1"},{"doi-asserted-by":"crossref","unstructured":"Guerrero-Mac\u00edas, S, Pinilla-Morales, R, Facundo-Navia, H, Manrique-Acevedo, ME, Rend\u00f3n-Hern\u00e1ndez, J, Rey-Ferro, M, et al.. Situaci\u00f3n actual de La laparoscop\u00eda de estadificaci\u00f3n en pacientes con c\u00e1ncer g\u00e1strico en Colombia: \u00bfc\u00f3mo lo estamos haciendo? Rev Colomb Cir 2023;38:74\u201383. https:\/\/doi.org\/10.30944\/20117582.2182.","key":"2025092318543928012_j_pp-2025-0005_ref_012","DOI":"10.30944\/20117582.2182"},{"doi-asserted-by":"crossref","unstructured":"Choi, AH, Kim, J, Chao, J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol 2015;21:7343\u20138. https:\/\/doi.org\/10.3748\/wjg.v21.i24.7343.","key":"2025092318543928012_j_pp-2025-0005_ref_013","DOI":"10.3748\/wjg.v21.i24.7343"},{"doi-asserted-by":"crossref","unstructured":"Fallah, M, Detlefsen, S, Ainsworth, AP, Fristrup, CW, Mortensen, MB, Pfeiffer, P, et al.. Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum 2022;7:143\u20138. https:\/\/doi.org\/10.1515\/pp-2022-0108.","key":"2025092318543928012_j_pp-2025-0005_ref_014","DOI":"10.1515\/pp-2022-0108"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0005\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0005\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T18:55:07Z","timestamp":1758653707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0005\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,23]]},"published-print":{"date-parts":[[2025,9,24]]}},"alternative-id":["10.1515\/pp-2025-0005"],"URL":"https:\/\/doi.org\/10.1515\/pp-2025-0005","relation":{},"ISSN":["2364-7671","2364-768X"],"issn-type":[{"type":"print","value":"2364-7671"},{"type":"electronic","value":"2364-768X"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}